CLINICAL SIGHNIFICANCE OF ADIPONECTINEMIA IN DEVELOPMENT OF TARGET ORGAN-DAMAGE IN METABOLIC SYNDROME, ASSOCIATED WITH NON-ALCOHOLIC FATTY LIVER DISEASE
- Authors: Saginova EA1, Severova MM1, Gallyamov MG1, Ermakov NV1, Rodina AV1, Fomin VV1, Mukhin NA1
-
Affiliations:
- Issue: No 6 (2011)
- Pages: 36-41
- Section: Articles
- URL: https://journals.eco-vector.com/2075-3594/article/view/246014
- ID: 246014
Cite item
Full Text
Abstract
Aim. Assessment of clinical significance of plasma adiponectin level in development of target organ damage (TOD) in metabolic syndrome, associated with non-alcoholic fatty liver disease.
Methods. 86 patients (64 male, 22 female; mean age 44+11 years) with metabolic syndrome, associated with non-alcoholic fatty liver disease (ultrasound features of hepatic stetatosis and/or non-alcoholic steatohepatitis) were included into the study. Risk factors and plasma levels of leptin and adiponectin were determined.
Results. Frequency of left ventricular hypertrophy, carotid atherosclerosis and chronic kidney disease increaser significantly according to the elevation of number of signs of target organ damage. Patients with >3 signs of target organ damage had the highest rate of non-alcoholic steatohepatitis (78% vs 39% in patients with 1 sign of TOD, р<0,05). Increase in number of signs of TOD was associated with elevation of leptin/adiponectin ratio. Plasma level of adiponectin significantly decreased in patients with carotid atherosclerosis (14,9±10,8 vs 32,5±22,5 mcg/ml, р=0,005) and inversely correlated with intima-media thickness of common carotid artery. Plasma adiponectin level directle correlated with HDL plasma level, leptinemia and DeRitis ratio.
Conslusion. In metabolic syndrome, associated with non-alcoholic fatty liver disease, organoprotective effects of adiponectin gradually diminish, that leads to increase of intensity of TOD.
Methods. 86 patients (64 male, 22 female; mean age 44+11 years) with metabolic syndrome, associated with non-alcoholic fatty liver disease (ultrasound features of hepatic stetatosis and/or non-alcoholic steatohepatitis) were included into the study. Risk factors and plasma levels of leptin and adiponectin were determined.
Results. Frequency of left ventricular hypertrophy, carotid atherosclerosis and chronic kidney disease increaser significantly according to the elevation of number of signs of target organ damage. Patients with >3 signs of target organ damage had the highest rate of non-alcoholic steatohepatitis (78% vs 39% in patients with 1 sign of TOD, р<0,05). Increase in number of signs of TOD was associated with elevation of leptin/adiponectin ratio. Plasma level of adiponectin significantly decreased in patients with carotid atherosclerosis (14,9±10,8 vs 32,5±22,5 mcg/ml, р=0,005) and inversely correlated with intima-media thickness of common carotid artery. Plasma adiponectin level directle correlated with HDL plasma level, leptinemia and DeRitis ratio.
Conslusion. In metabolic syndrome, associated with non-alcoholic fatty liver disease, organoprotective effects of adiponectin gradually diminish, that leads to increase of intensity of TOD.
About the authors
E A Saginova
M M Severova
M G Gallyamov
N V Ermakov
A V Rodina
V V Fomin
N A Mukhin
References
- Ritchie S.A., Connell J.M. The link between abdominal obesity, metabolic syndrome and cardiovascular disease. Nutr. Metab. Cardiovasc. Dis. 2007; 17(4): 319-326
- Antuna-Puente B., Feve B., Fellahi S. Adipokines: the missing link between insulin resistance and obesity. Diabetes Metab. 2008; 34(1): 2-11
- Anubhuti, Arora S. Leptin and its metabolic interactions: an update. Diabetes Obes. Metab. 2008; 10(11): 973-993
- Han S.H., Sakuma I., Shin E.K., Koh K.K. Antiatherosclerotic and anti-insulin resistance effects of adiponectin: basic and clinical studies. Prog Cardiovasc Dis. 2009; 52(2): 126-140
- Han S.H., Quon M.J., Kim J.A., Koh K.K. Adiponectin and cardiovascular disease: response to therapeutic interventions. J. Am. Coll. Cardiol. 2007; 49(5): 531-538
- Комитет экспертов ВНОК. Диагностика и лечение метаболического синдрома. Российские рекомендации. М., 2009
- Комитет экспертов РМОАГ/ВНОК. Диагностика и лечение артериальной гипертензии. (Рекомендации Российского медицинского общества по артериальной гипертонии и Всероссийского научного общества кардиологов). Системные гипертензии. 2010; 3: 5 - 26
- Huang Y., Chen Y., Xu M. et al. Low-grade albuminuria is associated with carotid intima-media thickness in Chinese type 2 diabetic patients. J. Clin. Endocrinol. Metab. 2010; 95(11): 5122-5128
- Wachtell K., Olsen M.H., Dahlöf B. et al. Microalbuminuria in hypertensive patients with electrocardiographic left ventricular hypertrophy: the LIFE study. J. Hypertens. 2002; 20(3): 405-412
- Yasui K., Sumida Y., Mori Y. et al. Nonalcoholic steatohepatitis and increased risk of chronic kidney disease. Metabolism. 2010 Sep 1. [Epub ahead of print]
- Chang Y., Ryu S., Sung E. et al. Nonalcoholic fatty liver disease predicts chronic kidney disease in nonhypertensive and nondiabetic Korean men. Metabolism. 2008; 57(4): 569-576
- Targher G., Chonchol M., Bertolini L. et al. Increased risk of CKD among type 2 diabetics with nonalcoholic fatty liver disease. J. Am. Soc. Nephrol. 2008; 19(8): 1564-1570
- Goland S., Shimoni S., Zornitzki T. et al. Cardiac abnormalities as a new manifestation of nonalcoholic fatty liver disease: echocardiographic and tissue Doppler imaging assessment. J. Clin. Gastroenterol. 2006; 40(10): 949-955
- Salvi P., Ruffini R., Agnoletti D. et al. Increased arterial stiffness in nonalcoholic fatty liver disease: the Cardio-GOOSE study. J. Hypertens. 2010; 28(8): 1699-1707
- Kim H.C., Kim D.J., Huh K.B. Association between nonalcoholic fatty liver disease and carotid intima-media thickness according to the presence of metabolic syndrome. Atherosclerosis. 2009; 204(2): 521-525
- Wolf G, Ziyadeh FN. Leptin and renal fibrosis. Contrib Nephrol. 2006; 151:175-183.
- Мухин Н.А., Фомин В.В., Сагинова Е.А. и др. Эндотелиальная дисфункция и поражение почек при ожирении. Вестник РАМН 2006; 12: 25 - 31
- Oda N., Imamura S., Fujita T. et al. The ratio of leptin to adiponectin can be used as an index of insulin resistance. Metabolism. 2008; 57(2): 268-273
- Thorand B., Zierer A., Baumert J. et al. Associations between leptin and the leptin / adiponectin ratio and incident Type 2 diabetes in middle-aged men and women: results from the MONICA / KORA Augsburg study 1984-2002. Diabet. Med. 2010 Sep; 27(9): 1004-1011
- Saarikoski L.A., Huupponen R.K., Viikari JS. et al. Adiponectin is related with carotid artery intima-media thickness and brachial flow-mediated dilatation in young adults - the Cardiovascular Risk in Young Finns Study. Ann. Med. 2010; 42(8): 603-611
- Huang S.S., Huang P.H., Chen Y.H. et al. Association of adiponectin with future cardiovascular events in patients after acute myocardial infarction. J. Atheroscler. Thromb. 2010; 17(3): 295-303
- Norata G.D., Raselli S., Grigore L. et al. Leptin:adiponectin ratio is an independent predictor of intima media thickness of the common carotid artery. Stroke. 2007; 38(10): 2844-2846
- Cesari M., Pessina A.C., Zanchetta M. et al. Low plasma adiponectin is associated with coronary artery disease but not with hypertension in high-risk nondiabetic patients. J. Intern. Med. 2006; 260(5): 474-483
- Hashimoto N., Kanda J., Nakamura T. et al. Association of hypoadiponectinemia in men with early onset of coronary heart disease and multiple coronary artery stenoses. Metabolism. 2006; 55(12): 1653-1657
- Uribe M., Zamora-Valdés D., Moreno-Portillo M. et al. Hepatic expression of ghrelin and adiponectin and their receptors in patients with nonalcoholic fatty liver disease. Ann. Hepatol. 2008; 7(1): 67-71
- Hindle A.K., Edwards C., Mendonsa A. et al. Adiponectin but not leptin is involved in early hepatic disease in morbidly obese patients. Surg. Endosc. 2010; 24(7): 1547-1551
- Ma H., Gomez V., Lu L. et al. Expression of adiponectin and its receptors in livers of morbidly obese patients with non-alcoholic fatty liver disease. J. Gastroenterol. Hepatol. 2009; 24(2): 233-237
- Jiang L.L., Li L., Hong X.F. et al. Patients with nonalcoholic fatty liver disease display increased serum resistin levels and decreased adiponectin levels. Eur. J. Gastroenterol. Hepatol. 2009; 21(6): 662-666
Supplementary files
